HomeCompareRGHYX vs MRK

RGHYX vs MRK: Dividend Comparison 2026

RGHYX yields 6.63% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $25.8K in total portfolio value· pulled ahead in Year 4
10 years
RGHYX
RGHYX
● Live price
6.63%
Share price
$9.82
Annual div
$0.65
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.0K
Annual income
$1,011.13
Full RGHYX calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — RGHYX vs MRK

📍 MRK pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRGHYXMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RGHYX + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RGHYX pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RGHYX
Annual income on $10K today (after 15% tax)
$563.72/yr
After 10yr DRIP, annual income (after tax)
$859.46/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $7,468.95/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RGHYX + MRK for your $10,000?

RGHYX: 50%MRK: 50%
100% MRK50/50100% RGHYX
Portfolio after 10yr
$43.9K
Annual income
$5,404.63/yr
Blended yield
12.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

RGHYX
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RGHYX buys
0
MRK buys
0
No recent congressional trades found for RGHYX or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRGHYXMRK
Forward yield6.63%2.76%
Annual dividend / share$0.65$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$31.0K$56.8K
Annual income after 10y$1,011.13$9,798.13
Total dividends collected$8.4K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RGHYX vs MRK ($10,000, DRIP)

YearRGHYX PortfolioRGHYX Income/yrMRK PortfolioMRK Income/yrGap
1$11,363$663.20$11,206$366.19+$157.00RGHYX
2$12,863$704.30$12,650$502.35+$213.00RGHYX
3$14,508$745.10$14,407$694.19+$101.00RGHYX
4← crossover$16,309$785.44$16,585$967.82$276.00MRK
5$18,276$825.18$19,342$1,363.89$1.1KMRK
6$20,420$864.20$22,913$1,947.19$2.5KMRK
7$22,752$902.39$27,662$2,823.89$4.9KMRK
8$25,284$939.66$34,159$4,173.35$8.9KMRK
9$28,030$975.92$43,337$6,308.80$15.3KMRK
10$31,003$1,011.13$56,776$9,798.13$25.8KMRK

RGHYX vs MRK: Complete Analysis 2026

RGHYXStock

The investment seeks to achieve a high level of total return consisting of income and capital appreciation. The fund normally invests at least 80% of its assets in fixed income securities and/or investments that, at the time of purchase, have similar economic characteristics as fixed income securities that are non-investment grade (high yield /junk bond), and are considered by the adviser to have the potential to provide a high level of total return. Up to 20% of the fund&#39;s total assets may be invested in other securities, including investment grade securities.

Full RGHYX Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this RGHYX vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RGHYX vs SCHDRGHYX vs JEPIRGHYX vs ORGHYX vs KORGHYX vs MAINRGHYX vs JNJRGHYX vs ABBVRGHYX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.